EirGenix Inc., a Taiwan-based biopharmaceutical and CDMO company, has signed a second global exclusive licensing agreement with Sandoz AG for the commercialization of its pertuzumab biosimilar EG1206A, developed as an alternative to Roche’s Perjeta. The deal covers all global markets except Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, and Japan, further strengthening the companies’ collaboration on HER2-targeted therapies.

Under the agreement, EirGenix will receive up to USD 152 million in upfront and milestone payments, along with profit-sharing and performance-based sales incentives once the product launches. EirGenix will handle development, manufacturing, and supply.

EG1206A has completed its PK study and recently received positive regulatory feedback from both the US FDA and EMA, qualifying the product for an abbreviated pathway and waiving phase III comparative efficacy trials. This marks a major milestone in EirGenix’s biosimilar strategy.

The partnership builds on the companies’ earlier global agreement for trastuzumab biosimilar EG12014, already approved in Europe and under FDA review. With around 2.3 million breast cancer patients globally—20% of whom are HER2-positive—the combination of trastuzumab and pertuzumab remains a standard treatment, with emerging data suggesting expanded future use.

EirGenix’s growing HER2 biosimilar pipeline, supported by strong technical capabilities and expanding manufacturing capacity, positions the company as an increasingly significant global player in the biosimilar market.